These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 14968145)

  • 1. Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.
    Coyle D; Rodby RA
    Can J Cardiol; 2004 Jan; 20(1):71-9. PubMed ID: 14968145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Bilous RW
    J Hum Hypertens; 2004 Oct; 18(10):733-8. PubMed ID: 15116142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
    Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
    Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
    Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
    Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
    Frei A; Palmer AJ; Burnier M; Hess B
    Praxis (Bern 1994); 2006 Mar; 95(11):401-8. PubMed ID: 16570646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
    Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
    Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-efectiveness of Ibersartan in type II diabetic nephropathy with hypertension. A Spanish perspective].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; de Alvaro F;
    Nefrologia; 2004; 24(3):231-8. PubMed ID: 15283313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy.
    Annemans L; Demarteau N; Hu S; Lee TJ; Morad Z; Supaporn T; Yang WC; Palmer AJ
    Value Health; 2008; 11(3):354-64. PubMed ID: 17888064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH
    Diabetes Care; 2004 Aug; 27(8):1897-903. PubMed ID: 15277414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
    Rodby RA; Chiou CF; Borenstein J; Smitten A; Sengupta N; Palmer AJ; Roze S; Annemans L; Simon TA; Chen RS; Lewis EJ;
    Clin Ther; 2003 Jul; 25(7):2102-19. PubMed ID: 12946554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
    Palmer AJ; Valentine WJ; Ray JA
    Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
    Palmer AJ; Roze S; Valentine WJ; Ray JA; Frei A; Burnier M; Hess B; Spinas GA; Brändle M
    Swiss Med Wkly; 2006 May; 136(21-22):346-52. PubMed ID: 16779715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
    Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ;
    Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studies.
    Palmer AJ; Tucker DM; Valentine WJ; Roze S; Gabriel S; Cordonnier DJ
    Nephrol Dial Transplant; 2005 Jun; 20(6):1103-9. PubMed ID: 15855214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
    Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
    Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
    Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
    Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.